HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by White, J. R. Articles by Campbell, R. K. Search for Related Content PubMed Articles by White, J. R., Jr. Articles by Campbell, R. K. Social Bookmarking                What's this?

Recent Developments in the Pharmacological Reduction of Blood Glucose in Patients With Type 2 Diabetes

IN BRIEF

The pharmacological management of type 2 diabetes has changed dramatically in the past few years with the introduction of many new medications, including -glucosidase inhibitors, a biguanide, the thiazolidinediones, insulin analogs, meglitinides, and d-phenylalanine derivatives. These new agents have dramatically increased the number of options available to providers and patients. Combination therapy has become commonplace for the management of hyperglycemia in patients with type 2 diabetes. This article briefly reviews some of the more recent pharmacological advances in diabetes care.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. R. White Jr., S. N. Davis, R. Cooppan, M. B. Davidson, K. Mulcahy, G. A. Manko, and D. Nelinson Clarifying the Role of Insulin in Type 2 Diabetes Management Clin. Diabetes, January 1, 2003; 21(1): 14 - 21. [Abstract] [Full Text] [PDF]